Van ECK Associates Corp lifted its stake in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 9.4% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 123,100 shares of the biotechnology company’s stock after acquiring an additional 10,598 shares during the period. Van ECK Associates Corp owned 0.28% of United Therapeutics worth $14,426,000 as of its most recent filing with the Securities & Exchange Commission.
Other hedge funds and other institutional investors also recently bought and sold shares of the company. HPM Partners LLC raised its holdings in United Therapeutics by 0.8% in the 2nd quarter. HPM Partners LLC now owns 1,981 shares of the biotechnology company’s stock valued at $257,000 after buying an additional 15 shares during the period. First Allied Advisory Services Inc. increased its stake in United Therapeutics by 0.4% during the second quarter. First Allied Advisory Services Inc. now owns 4,579 shares of the biotechnology company’s stock worth $598,000 after purchasing an additional 19 shares during the period. Synovus Financial Corp increased its stake in United Therapeutics by 1.2% during the second quarter. Synovus Financial Corp now owns 5,639 shares of the biotechnology company’s stock worth $731,000 after purchasing an additional 69 shares during the period. Ifrah Financial Services Inc. increased its stake in United Therapeutics by 1.7% during the second quarter. Ifrah Financial Services Inc. now owns 4,437 shares of the biotechnology company’s stock worth $576,000 after purchasing an additional 76 shares during the period. Finally, Alps Advisors Inc. increased its stake in United Therapeutics by 2.3% during the second quarter. Alps Advisors Inc. now owns 3,827 shares of the biotechnology company’s stock worth $496,000 after purchasing an additional 86 shares during the period. Institutional investors and hedge funds own 99.94% of the company’s stock.
UTHR has been the topic of a number of recent research reports. Oppenheimer reiterated a “buy” rating on shares of United Therapeutics in a research note on Friday, September 8th. ValuEngine raised United Therapeutics from a “hold” rating to a “buy” rating in a research report on Monday, October 2nd. BidaskClub raised United Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday. Zacks Investment Research raised United Therapeutics from a “strong sell” rating to a “hold” rating in a report on Monday, October 9th. Finally, HC Wainwright reaffirmed a “hold” rating and issued a $95.00 price target on shares of United Therapeutics in a report on Thursday, October 26th. Three research analysts have rated the stock with a sell rating, eight have issued a hold rating and three have given a buy rating to the company’s stock. United Therapeutics currently has a consensus rating of “Hold” and a consensus target price of $136.10.
United Therapeutics Corporation (NASDAQ UTHR) opened at $134.17 on Wednesday. The stock has a market capitalization of $5,791.15, a price-to-earnings ratio of 11.82 and a beta of 1.42. United Therapeutics Corporation has a 52-week low of $112.01 and a 52-week high of $169.89.
United Therapeutics (NASDAQ:UTHR) last posted its earnings results on Wednesday, October 25th. The biotechnology company reported $6.27 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $4.01 by $2.26. The company had revenue of $445.50 million for the quarter, compared to analyst estimates of $426.43 million. United Therapeutics had a return on equity of 26.24% and a net margin of 30.50%. United Therapeutics’s revenue was up 9.1% compared to the same quarter last year. During the same quarter in the prior year, the company earned $4.23 earnings per share. analysts expect that United Therapeutics Corporation will post 12.45 earnings per share for the current fiscal year.
In related news, CEO Martine A. Rothblatt sold 1,241 shares of the stock in a transaction on Thursday, November 30th. The stock was sold at an average price of $128.95, for a total transaction of $160,026.95. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Martine A. Rothblatt sold 1,232 shares of the stock in a transaction on Thursday, September 7th. The shares were sold at an average price of $133.32, for a total value of $164,250.24. Following the sale, the chief executive officer now directly owns 2,301 shares in the company, valued at approximately $306,769.32. The disclosure for this sale can be found here. Insiders sold 23,900 shares of company stock worth $2,919,517 in the last three months. 7.80% of the stock is owned by corporate insiders.
TRADEMARK VIOLATION NOTICE: This news story was originally posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this news story on another domain, it was illegally stolen and republished in violation of U.S. and international copyright and trademark legislation. The original version of this news story can be accessed at https://ledgergazette.com/2017/12/06/united-therapeutics-corporation-uthr-holdings-raised-by-van-eck-associates-corp.html.
About United Therapeutics
United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).
Receive News & Ratings for United Therapeutics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.